Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US9701747B2 · kind B2 · utility
14Cited by
110References
15Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Sep 13, 2013 |
| Grant date | Jul 11, 2017 |
| Priority date | — |
| Expiry date | Dec 17, 2033 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.